Next Article in Journal
Anticancer Effects of Green Tea and the Underlying Molecular Mechanisms in Bladder Cancer
Next Article in Special Issue
Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis
Previous Article in Journal
Individual Differences in Responsiveness to Acupuncture: An Exploratory Survey of Practitioner Opinion
Previous Article in Special Issue
Effectiveness of Raw, Natural Medical Cannabis Flower for Treating Insomnia under Naturalistic Conditions
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessPerspective
Medicines 2018, 5(3), 86; https://doi.org/10.3390/medicines5030086

The Role of Cannabis within an Emerging Perspective on Schizophrenia

1
Department of Psychology, University of New Mexico, Albuquerque, NM 87131, USA
2
Department of Economics, University of New Mexico, Albuquerque, NM 87131, USA
*
Author to whom correspondence should be addressed.
Received: 10 June 2018 / Revised: 6 July 2018 / Accepted: 31 July 2018 / Published: 8 August 2018
(This article belongs to the Special Issue Cannabinoids for Medical Use)
Full-Text   |   PDF [285 KB, uploaded 8 August 2018]

Abstract

Background: Approximately 0.5% of the population is diagnosed with some form of schizophrenia, under the prevailing view that the pathology is best treated using pharmaceutical medications that act on monoamine receptors. Methods: We briefly review evidence on the impact of environmental forces, particularly the effect of autoimmune activity, in the expression of schizophrenic profiles and the role of Cannabis therapy for regulating immunological functioning. Results: A review of the literature shows that phytocannabinoid consumption may be a safe and effective treatment option for schizophrenia as a primary or adjunctive therapy. Conclusions: Emerging research suggests that Cannabis can be used as a treatment for schizophrenia within a broader etiological perspective that focuses on environmental, autoimmune, and neuroinflammatory causes of the disorder, offering a fresh start and newfound hope for those suffering from this debilitating and poorly understood disease. View Full-Text
Keywords: schizophrenia; cannabis; marijuana; autoimmunity; monoamine therapy; mental illness; cannabidiol; tetrahydrocannabinol; endocannabinoid system schizophrenia; cannabis; marijuana; autoimmunity; monoamine therapy; mental illness; cannabidiol; tetrahydrocannabinol; endocannabinoid system
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Diviant, J.P.; Vigil, J.M.; Stith, S.S. The Role of Cannabis within an Emerging Perspective on Schizophrenia. Medicines 2018, 5, 86.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top